Clinically relevant SMAC mimetics do not enhance human T cell proliferation or cytokine production
Burton, A.; Ligman, B.; Kearney, C.; Murray, S. E.
Show abstract
Secondary mitochondria-derived activator of caspases (SMAC) mimetics are being tested in dozens of clinical trials to treat cancer. These targeted therapies mimic endogenous molecules that promote apoptosis by antagonizing inhibitors of apoptosis (IAPs), which are commonly overexpressed in cancer cells. In T cells, IAPs function to restrain non-canonical NF-kB signaling. Thus, it has been suggested that in addition to their direct anti-cancer mechanism of action, SMAC mimetics may activate T cells, thereby promoting anti-tumor immunity. Here, we tested the effect of three clinically relevant SMAC mimetics on the proliferation and activation of primary human T cells. As previously reported, SMAC mimetics killed tumor cells and activated non-canonical NF-kB in T cells at clinically relevant doses. Surprisingly, none of the SMAC mimetics augmented T cell proliferation or effector function. These results question the assumption that SMAC mimetics are likely to boost anti-tumor immunity in cancer patients.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- NF-kB c-Rel is dispensable for the development but is required for the cytotoxic function of NK cells 95%
- Exploration of T-cell immune responses by expression of a dominant-negative SHP1 and SHP2 95%
- Rituximab-IgG2 is a phagocytic enhancer in antibody-based immunotherapy of B-cell lymphoma by altering CD47 expression 95%
Similar papers in this journal
- Insulin-like Growth Factor-1 Synergizes with IL-2 to Induce Homeostatic Proliferation of Regulatory T cells 93%
- Soluble FAS Ligand directs human memory B cells towards antibody-secreting cells 93%
- Treg cells maintain selective access to IL-2 and immune homeostasis despite substantially reduced CD25 function 92%
Similar papers in this journal
- DOK1 and DOK2 regulate CD8+ T cell signaling and memory formation without affecting tumor cell killing 94%
- Small molecule inhibition of human cGAS reduces total cGAMP output and cytokine expression in cells 93%
- Tozorakimab (MEDI3506): a dual-pharmacology anti-IL-33 antibody that inhibits IL-33 signalling via ST2 and RAGE/EGFR to reduce inflammation and epithelial dysfunction 92%
Similar papers in this journal
- Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity 93%
- Domain Binding and Isotype Dictate the Activity of Anti-human OX40 Antibodies 93%
- TIM-3 blockade enhances ex vivo stimulated allogeneic NK cell therapy for relapsed murine neuroblastoma after hematopoietic cell transplant 93%
Similar papers in this journal
- A mechanistically novel peptide agonist of the IL-7 receptor that addresses limitations of IL-7 cytokine therapy 96%
- The Ca2+ concentration in vitro impacts the cytokine production of mouse and human lymphoid cells and the polarization of human macrophages 95%
- A phosphoramidate modification of FUDR, NUC-3373, causes DNA damage and DAMPs release from colorectal cancer cells, potentiating lymphocyte-induced cell death 94%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.